- Home
- TACT vs KZR Comparison
TACT vs KZR Comparison
Compare TACT & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- KZR
- Stock Information
- Founded
- TACT 1996
- KZR 2015
- Country
- TACT United States
- KZR United States
- Employees
- TACT N/A
- KZR N/A
- Industry
- TACT Computer peripheral equipment
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- KZR Health Care
- Exchange
- TACT Nasdaq
- KZR Nasdaq
- Market Cap
- TACT 40.9M
- KZR 46.5M
- IPO Year
- TACT 1996
- KZR 2018
- Fundamental
- Price
- TACT $4.50
- KZR $6.40
- Analyst Decision
- TACT Strong Buy
- KZR Hold
- Analyst Count
- TACT 1
- KZR 2
- Target Price
- TACT $7.50
- KZR $9.00
- AVG Volume (30 Days)
- TACT 18.5K
- KZR 48.3K
- Earning Date
- TACT 03-11-2025
- KZR 03-13-2025
- Dividend Yield
- TACT N/A
- KZR N/A
- EPS Growth
- TACT N/A
- KZR N/A
- EPS
- TACT N/A
- KZR N/A
- Revenue
- TACT $46,418,000.00
- KZR N/A
- Revenue This Year
- TACT N/A
- KZR N/A
- Revenue Next Year
- TACT $16.86
- KZR N/A
- P/E Ratio
- TACT N/A
- KZR N/A
- Revenue Growth
- TACT N/A
- KZR N/A
- 52 Week Low
- TACT $3.32
- KZR $5.20
- 52 Week High
- TACT $7.97
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- TACT 61.71
- KZR 42.57
- Support Level
- TACT $4.31
- KZR $6.16
- Resistance Level
- TACT $4.60
- KZR $6.63
- Average True Range (ATR)
- TACT 0.18
- KZR 0.28
- MACD
- TACT 0.03
- KZR -0.01
- Stochastic Oscillator
- TACT 62.86
- KZR 23.08
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.